BRPI0823377A2 - análogos de glucagon - Google Patents
análogos de glucagonInfo
- Publication number
- BRPI0823377A2 BRPI0823377A2 BRPI0823377A BRPI0823377A BRPI0823377A2 BR PI0823377 A2 BRPI0823377 A2 BR PI0823377A2 BR PI0823377 A BRPI0823377 A BR PI0823377A BR PI0823377 A BRPI0823377 A BR PI0823377A BR PI0823377 A2 BRPI0823377 A2 BR PI0823377A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucagon analogs
- glucagon
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2008/004157 WO2010070255A1 (en) | 2008-12-15 | 2008-12-15 | Glucagon analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0823377A2 true BRPI0823377A2 (pt) | 2016-09-27 |
Family
ID=40418466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0823377A BRPI0823377A2 (pt) | 2008-12-15 | 2008-12-15 | análogos de glucagon |
Country Status (17)
Country | Link |
---|---|
US (1) | US8680049B2 (pt) |
EP (1) | EP2370462B1 (pt) |
JP (1) | JP5635532B2 (pt) |
KR (1) | KR101593406B1 (pt) |
CN (1) | CN102292348B (pt) |
AU (1) | AU2008365559B2 (pt) |
BR (1) | BRPI0823377A2 (pt) |
CA (1) | CA2747197A1 (pt) |
DK (1) | DK2370462T3 (pt) |
EA (1) | EA020596B1 (pt) |
ES (1) | ES2502218T3 (pt) |
IL (1) | IL213478A0 (pt) |
MX (1) | MX2011006315A (pt) |
NZ (1) | NZ593813A (pt) |
PL (1) | PL2370462T3 (pt) |
WO (1) | WO2010070255A1 (pt) |
ZA (1) | ZA201104593B (pt) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY160219A (en) | 2008-12-15 | 2017-02-28 | Zealand Pharma As | Glucagon analogues |
US8642541B2 (en) | 2008-12-15 | 2014-02-04 | Zealand Pharma A/S | Glucagon analogues |
DK2370460T3 (da) | 2008-12-15 | 2014-08-04 | Zealand Pharma As | Glucagon analoger |
RS53987B1 (en) | 2009-07-13 | 2015-10-30 | Zealand Pharma A/S | ANALYSIS OF ACYLATED GLUCAGON |
JP5969461B2 (ja) | 2010-04-27 | 2016-08-17 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用 |
AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
NZ604208A (en) | 2010-06-24 | 2014-10-31 | Zealand Pharma As | Glucagon analogues |
US20140011733A1 (en) * | 2011-01-20 | 2014-01-09 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
JP6396211B2 (ja) | 2011-07-04 | 2018-09-26 | インペリアル・イノベイションズ・リミテッド | 新規化合物及び摂食行動に対するそれらの効果 |
IN2014CN02448A (pt) | 2011-09-23 | 2015-06-19 | Novo Nordisk As | |
WO2013064669A1 (en) | 2011-11-03 | 2013-05-10 | Zealand Pharma A/S | Glp-1 receptor agonist peptide gastrin conjugates |
US20130316941A1 (en) * | 2011-12-23 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Glucagon analogues |
TWI689515B (zh) | 2012-05-03 | 2020-04-01 | 丹麥商西蘭製藥公司 | Gip-glp-1雙重促效劑化合物及方法 |
CN112142855A (zh) | 2012-05-18 | 2020-12-29 | 爱德迪安(北京)生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
KR20150023690A (ko) | 2012-06-14 | 2015-03-05 | 사노피 | 엑센딘-4 펩타이드 유사체 |
KR102129235B1 (ko) | 2012-07-23 | 2020-07-06 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
SG11201503526UA (en) | 2012-12-21 | 2015-06-29 | Sanofi Sa | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
MX363522B (es) | 2013-03-21 | 2019-03-26 | Sanofi Aventis Deutschland | Síntesis de productos peptídicos que contienen hidantoína. |
ES2624961T3 (es) | 2013-03-21 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Síntesis de productos de péptido que contienen imida cíclica |
AR095986A1 (es) | 2013-04-03 | 2015-11-25 | Sanofi Sa | Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas |
KR20160021758A (ko) | 2013-04-18 | 2016-02-26 | 노보 노르디스크 에이/에스 | 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
KR102569036B1 (ko) | 2013-10-17 | 2023-08-23 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
CA2932477C (en) | 2013-12-06 | 2023-10-10 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
EP3080155A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
JP6018129B2 (ja) * | 2014-07-04 | 2016-11-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
CN107001439B (zh) | 2014-10-29 | 2021-12-21 | 西兰制药公司 | Gip激动剂化合物及方法 |
SG11201705640PA (en) | 2015-02-17 | 2017-08-30 | Lilly Co Eli | Nasal powder formulation for treatment of hypoglycemia |
EP3271381B1 (en) | 2015-03-18 | 2021-09-08 | Zealand Pharma A/S | Amylin analogues |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
EP3283507B8 (en) | 2015-04-16 | 2019-11-13 | Zealand Pharma A/S | Acylated glucagon analogue |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
CN105968186B (zh) * | 2016-06-02 | 2020-10-30 | 中国药科大学 | 具有长效化作用的胰高血糖素(Glu)类似物及其应用 |
PE20190414A1 (es) | 2016-08-05 | 2019-03-19 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) |
AR109514A1 (es) | 2016-09-09 | 2018-12-19 | Zealand Pharma As | Análogos de amilina |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
CN117603337A (zh) * | 2017-08-16 | 2024-02-27 | 东亚St株式会社 | 酰化胃泌酸调节素肽类似物 |
EP3517543B1 (en) * | 2018-01-30 | 2020-11-04 | Bachem AG | Manufacture of glucagon peptides |
CA3087827A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
JP7225253B2 (ja) | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
SG11202006125VA (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
PE20210658A1 (es) | 2018-02-02 | 2021-03-31 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) |
WO2020074583A1 (en) | 2018-10-09 | 2020-04-16 | Fresenius Kabi Ipsum S.R.L. | Process for the manufacture of glp-1 analogues |
WO2020125744A1 (zh) | 2018-12-21 | 2020-06-25 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
EP3753946A1 (en) | 2019-06-18 | 2020-12-23 | Fresenius Kabi iPSUM S.r.l. | Improved process for the preparation of high purity glucagon |
CN114401981A (zh) * | 2019-06-18 | 2022-04-26 | 北京费森尤斯卡比医药有限公司 | 胰高血糖素制造方法 |
PE20221168A1 (es) | 2019-11-11 | 2022-07-25 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
BR112022021765A2 (pt) * | 2020-04-29 | 2022-12-13 | Onegene Biotechnology Inc | Conjugado de proteína, composição farmacêutica, método para prevenção ou tratamento de esteato-hepatite não alcoólica, fígado gorduroso, fibrose hepática, cirrose, câncer de fígado, obesidade ou diabetes, método para preparação de um conjugado de proteína |
IL300239A (en) | 2020-08-07 | 2023-03-01 | Boehringer Ingelheim Int | Soluble NPY2 receptor agonists |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
DK0944648T3 (da) | 1996-08-30 | 2007-07-02 | Novo Nordisk As | GLP-1 derivater |
AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
JP2001505872A (ja) | 1996-09-09 | 2001-05-08 | ジーランド ファーマシューティカルズ アクティーゼルスカブ | α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ |
DE69838916T2 (de) | 1997-11-14 | 2008-12-18 | Amylin Pharmaceuticals, Inc., San Diego | Neuartige exendin agonisten |
EP1950223A3 (en) | 1998-03-09 | 2009-05-13 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
IL143346A0 (en) * | 1998-12-07 | 2002-04-21 | Sod Conseils Rech Applic | Analogues of glp-1 |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
RU2001128068A (ru) | 1999-03-17 | 2004-02-20 | Ново Нордиск А/С (DK) | Способ ацилирования пептидов и новые ацилирующие агенты |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
MXPA04006084A (es) | 2001-12-20 | 2005-03-31 | Lilly Co Eli | Molecula de insulina que tiene una accion en el tiempo prolongada. |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
WO2004096854A2 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
EP2351776A1 (en) | 2005-06-13 | 2011-08-03 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
ES2507098T3 (es) * | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
JP5297817B2 (ja) | 2006-02-22 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | オキシントモジュリン誘導体 |
EA020324B1 (ru) | 2006-07-18 | 2014-10-30 | Санофи-Авентис | АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ |
WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
CA2711749A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
WO2009087082A2 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
EP2296692A4 (en) | 2008-04-22 | 2012-06-06 | Univ Case Western Reserve | INSULIN ANALOGUES SPECIFIC TO ISOFORMS |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
AU2009260301B2 (en) | 2008-06-17 | 2015-09-03 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
CA2732439A1 (en) | 2008-07-31 | 2010-02-04 | Case Western Reserve University | Halogen-stabilized insulin |
DK2370460T3 (da) | 2008-12-15 | 2014-08-04 | Zealand Pharma As | Glucagon analoger |
MY160219A (en) | 2008-12-15 | 2017-02-28 | Zealand Pharma As | Glucagon analogues |
US8642541B2 (en) | 2008-12-15 | 2014-02-04 | Zealand Pharma A/S | Glucagon analogues |
EP2376521B1 (en) | 2008-12-19 | 2016-04-13 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
EP2376520B1 (en) | 2008-12-19 | 2014-02-12 | Indiana University Research&Technology Corporation | Insulin analogs |
CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
RS53987B1 (en) | 2009-07-13 | 2015-10-30 | Zealand Pharma A/S | ANALYSIS OF ACYLATED GLUCAGON |
AU2011206979B2 (en) | 2010-01-20 | 2015-09-10 | Zealand Pharma A/S | Treatment of cardiac conditions |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
NZ604208A (en) | 2010-06-24 | 2014-10-31 | Zealand Pharma As | Glucagon analogues |
US20140011733A1 (en) | 2011-01-20 | 2014-01-09 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
-
2008
- 2008-12-15 NZ NZ593813A patent/NZ593813A/xx not_active IP Right Cessation
- 2008-12-15 ES ES08875673.9T patent/ES2502218T3/es active Active
- 2008-12-15 CN CN200880132702.8A patent/CN102292348B/zh not_active Expired - Fee Related
- 2008-12-15 CA CA2747197A patent/CA2747197A1/en not_active Abandoned
- 2008-12-15 PL PL08875673T patent/PL2370462T3/pl unknown
- 2008-12-15 MX MX2011006315A patent/MX2011006315A/es active IP Right Grant
- 2008-12-15 US US13/139,487 patent/US8680049B2/en not_active Expired - Fee Related
- 2008-12-15 BR BRPI0823377A patent/BRPI0823377A2/pt not_active IP Right Cessation
- 2008-12-15 AU AU2008365559A patent/AU2008365559B2/en not_active Ceased
- 2008-12-15 EP EP08875673.9A patent/EP2370462B1/en not_active Not-in-force
- 2008-12-15 WO PCT/GB2008/004157 patent/WO2010070255A1/en active Application Filing
- 2008-12-15 KR KR1020117016185A patent/KR101593406B1/ko not_active IP Right Cessation
- 2008-12-15 EA EA201190048A patent/EA020596B1/ru not_active IP Right Cessation
- 2008-12-15 DK DK08875673.9T patent/DK2370462T3/da active
- 2008-12-15 JP JP2011540190A patent/JP5635532B2/ja not_active Expired - Fee Related
-
2011
- 2011-06-12 IL IL213478A patent/IL213478A0/en unknown
- 2011-06-22 ZA ZA2011/04593A patent/ZA201104593B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201104593B (en) | 2015-01-28 |
EP2370462B1 (en) | 2014-07-16 |
JP2012511902A (ja) | 2012-05-31 |
US8680049B2 (en) | 2014-03-25 |
CA2747197A1 (en) | 2010-06-24 |
KR101593406B1 (ko) | 2016-02-12 |
EA020596B1 (ru) | 2014-12-30 |
AU2008365559A1 (en) | 2011-07-21 |
CN102292348B (zh) | 2015-07-08 |
EA201190048A1 (ru) | 2012-02-28 |
EP2370462A1 (en) | 2011-10-05 |
MX2011006315A (es) | 2011-09-22 |
WO2010070255A1 (en) | 2010-06-24 |
IL213478A0 (en) | 2011-07-31 |
JP5635532B2 (ja) | 2014-12-03 |
PL2370462T3 (pl) | 2015-01-30 |
KR20110126590A (ko) | 2011-11-23 |
ES2502218T3 (es) | 2014-10-03 |
CN102292348A (zh) | 2011-12-21 |
AU2008365559B2 (en) | 2016-02-25 |
DK2370462T3 (da) | 2014-09-08 |
US20110286981A1 (en) | 2011-11-24 |
NZ593813A (en) | 2013-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301058I2 (nl) | Brolucizumab | |
BRPI0823379A2 (pt) | Análogos de glucagon | |
BRPI0823377A2 (pt) | análogos de glucagon | |
BRPI0823378A2 (pt) | análogos de glucagon | |
BRPI0823376A2 (pt) | Análagos de glucagon | |
SMT201600351B (it) | Composti antivirali | |
BRPI0922508A2 (pt) | Análogos de nucleosídeo | |
SMT201600045B (it) | Composti tetraciclinici c7-fluoro sostituiti | |
DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
BRPI0911269A2 (pt) | análogos de halicondrina b | |
BRPI0920707A2 (pt) | compostos | |
DK2326651T3 (da) | Buprenorphinanaloger | |
DK2242759T3 (da) | Forbindelser | |
BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
BR112012006859A2 (pt) | compostos | |
DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
DK2427449T3 (da) | Vinylindazolylforbindelser | |
BRPI1005525A2 (pt) | compostos de azaazuleno | |
BRPI0910345A2 (pt) | análogos de oxitocina | |
DK2297162T3 (da) | Forbindelser | |
BRPI0907122A2 (pt) | Piridoindóis (1-azinona) substituídos | |
DK2490708T3 (da) | Stabiliserede glucagon-opløsninger | |
BRPI0918004A2 (pt) | antagonistas de glucagon | |
FI8206U1 (fi) | Kanylointisimulantti | |
CR10675A (es) | Analogos de 2-fenoxipirimidinona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |